These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2354227)

  • 61. Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients.
    Faraone SV; Brown WA; Laughren TP
    J Clin Psychiatry; 1987 Apr; 48(4):151-4. PubMed ID: 2881923
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.
    McEvoy JP; Hogarty GE; Steingard S
    Arch Gen Psychiatry; 1991 Aug; 48(8):739-45. PubMed ID: 1883257
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Ratio of serum prolactin to haloperidol and early clinical outcome in acute psychosis.
    Swigar ME; Jatlow PI; Goicoechea N; Opsahl C; Bowers MB
    Am J Psychiatry; 1984 Oct; 141(10):1281-3. PubMed ID: 6486269
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Heterogeneity of schizophrenia: relationship to latency of neuroleptic response.
    McDermott BE; Sautter FJ; Garver DL
    Psychiatry Res; 1991 Apr; 37(1):97-103. PubMed ID: 1862165
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The effect of thioridazine on prolactin levels in acutely schizophrenic patients: challenge-dose and steady-state levels.
    Johnson GF; Hunt GE
    Aust N Z J Psychiatry; 1980 Jun; 14(2):127-31. PubMed ID: 6932868
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Acutely psychotic patients receiving high-dose haloperidol therapy.
    Remington G; Pollock B; Voineskos G; Reed K; Coulter K
    J Clin Psychopharmacol; 1993 Feb; 13(1):41-5. PubMed ID: 8486816
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of subtle neurological dysfunction on response to haloperidol treatment in schizophrenia.
    Convit A; Volavka J; Czobor P; de Asis J; Evangelista C
    Am J Psychiatry; 1994 Jan; 151(1):49-56. PubMed ID: 8267134
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of propranolol treatment on serum prolactin level in schizophrenic patients.
    Elizur A; Segal Z; Yeret A; Ben-David M
    Commun Psychopharmacol; 1980; 4(3):203-6. PubMed ID: 7226751
    [No Abstract]   [Full Text] [Related]  

  • 69. Prolactin responses to neuroleptics in normal and schizophrenic subjects.
    Gruen PH; Sachar EJ; Langer G; Altman N; Leifer M; Frantz A; Halpern FS
    Arch Gen Psychiatry; 1978 Jan; 35(1):108-16. PubMed ID: 23087
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial.
    Gomez JC; Crawford AM
    J Clin Psychiatry; 2001; 62 Suppl 2():6-11. PubMed ID: 11232753
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy and side effects of haloperidol in psychotic patients: oral versus intravenous administration.
    Möller HJ; Kissling W; Lang C; Doerr P; Pirke KM; von Zerssen D
    Am J Psychiatry; 1982 Dec; 139(12):1571-5. PubMed ID: 7149056
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The effect of haloperidol on aldosterone secretion.
    Warner MD; Gillespie H; Pavlou SN; Nader S; Peabody CA
    Psychoneuroendocrinology; 1992 Oct; 17(5):517-21. PubMed ID: 1484918
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Plasma catecholamine metabolites and early response to haloperidol.
    Bowers MB; Swigar ME; Jatlow PI; Goicoechea N
    J Clin Psychiatry; 1984 Jun; 45(6):248-51. PubMed ID: 6725216
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prolactin regulation of tuberoinfundibular dopaminergic neurons: immunoneutralization studies.
    Hentschel K; Fleckenstein AE; Toney TW; Lawson DM; Moore KE; Lookingland KJ
    Brain Res; 2000 Jan; 852(1):28-36. PubMed ID: 10661492
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The Dose Reduction in Schizophrenia (DORIS) Study: a final report.
    Hirschowitz J; Hitzemann R; Piscani K; Burr G; Frecska E; Culliton D; Mann M; Curtis C
    Schizophr Res; 1997 Jan; 23(1):31-43. PubMed ID: 9050126
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Longitudinal instability of hormone responses in schizophrenia.
    Cleghorn JM; Brown GM; Brown PJ; Kaplan RD; Mitton J
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):545-9. PubMed ID: 6686692
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Standard and high doses of haloperidol. Clinical, pharmacokinetic and pharmacodynamic aspects].
    Schilkrut R; Haverbeck C; Duran E; Delgado S; Kohen P; Birkner R; Katz I
    Acta Psiquiatr Psicol Am Lat; 1981; 27(4-5):315-24. PubMed ID: 7348089
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Procedural validity of an abbreviated version of the SADS/RDC diagnostic process.
    Green RL; Price TR
    Psychiatry Res; 1986 Aug; 18(4):379-91. PubMed ID: 3749394
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The relationship of dopamine receptor blockade to clinical response in schizophrenic patients treated with pimozide or haloperidol.
    Silverstone T; Cookson J; Ball R; Chin CN; Jacobs D; Lader S; Gould S
    J Psychiatr Res; 1984; 18(3):255-68. PubMed ID: 6387105
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity.
    Chouinard G
    J Clin Psychopharmacol; 1987 Jun; 7(3):159-64. PubMed ID: 2885345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.